Norway's salmon farming industry faces escalating ISA and BKD outbreaks while sea lice treatment costs consume 10-20% of production value

As of mid-2024, most of Norway's largest salmon farming companies were simultaneously coping with outbreaks of infectious salmon anemia (ISA) and bacterial kidney disease (BKD) at higher-than-normal rates. Norway, which produces roughly 1.5 million tonnes of Atlantic salmon annually (over 50% of global supply), faces an escalating disease management crisis as pathogens adapt to intensive net-pen aquaculture densities. Why it matters: Disease outbreaks force mass culling of affected pens and movement restrictions on neighboring farms, so production losses and treatment costs -- particularly for sea lice, the most pressing issue facing the industry -- consume an estimated 10-20% of total production value annually across Norwegian operations, so companies pass costs to consumers while simultaneously increasing antibiotic and pesticide use that accumulates in coastal sediments, so net-pen aquaculture creates pathogen reservoirs that spill over to wild Atlantic salmon populations already at critically low levels in rivers across Norway, Scotland, and eastern Canada, so wild salmon face a dual threat of pathogen exposure from farms and weakened immune systems from warming waters driven by climate change. The structural root cause is that open net-pen aquaculture allows free exchange of water, pathogens, and parasites between farmed and wild fish populations, and the economic incentive structure rewards maximizing biomass density per pen rather than investing in closed-containment or land-based recirculating aquaculture systems (RAS) that would eliminate pathogen exchange but require 3-5x higher capital expenditure.